沙库巴曲缬沙坦联合美托洛尔对冠心病慢性心力衰竭患者心功能及血清sST2、AngII、IGFBP7水平的影响  

Effects of salkubatrol valsartan combined with metoprolol on cardiac function and serum levels of ST2,AngII and IGFBP7 in patients with coronary heart disease and chronic heart failure

作　　者：田瑞兆[1] 张春林[2] 杨鹏 王莉[1] TIAN Rui-zhao;ZHANG Chun-lin;YANG Peng;WANG Li(Department of Critical Medicine Gansu Provincial Cancer Hospital;Department of Radiotherapy,Gansu Provincial Academic Institute for Medical Research,Lanzhou 730050,Gansu,China)

机构地区：[1]甘肃省肿瘤医院重症医学科 [2]甘肃省医学科学研究院放疗科,甘肃兰州730050

出　　处：《川北医学院学报》2022年第1期59-62,共4页Journal of North Sichuan Medical College

基　　金：甘肃省科技计划项目(20YF3FA017)。

摘　　要：目的:探究沙库巴曲缬沙坦联合美托洛尔治疗对冠心病慢性心力衰竭(CHF)患者心功能及血清可溶性生长刺激表达基因2(sST2)蛋白、血管紧张素II(AngII)及胰岛素样生长因子结合蛋白7(IGFBP7)水平的影响。方法:按治疗方案的不同将100例冠心病CHF患者分为观察组和对照组,每组各50例。对照组采用美托洛尔治疗,观察组采用沙库巴曲缬沙坦联合美托洛尔治疗,连续治疗6个月。比较两组临床疗效,左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)及肱动脉血流介导血管舒张功能(FDM),血清内皮素-1(ET-1)、一氧化氮(NO)及sST2、AngII、IGFBP7水平;同时比较两组患者不良反应发生情况。结果:治疗后,观察组患者总有效率高于对照组(91.49%vs.77.42%,P<0.05);观察组LVEF、FMD均高于对照组(P<0.05),LVEDD、LVESD低于对照组(P<0.05);观察组血清sST2、AngII、ET-1低于对照组(P<0.05),IGFBP7、NO水平高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦联合美托洛尔可提高冠心病CHF治疗效果,增强患者心功能、血管内皮功能;同时对患者血清sST2、AngII、IGFBP7的表达也有一定的调控作用。Objective:To investigate the effects of salkubatroxartan combined with metoprolol on cardiac function and the levels of soluble ST2(sST2),angiotensin II(AngII) and insulin-like growth factor binding protein 7(IGFBP7) in patients with coronary heart disease and chronic heart failure(CHF).Methods:100 patients with CHF of coronary heart disease were divided into observation group and control group according to different treatment schemes,50 cases in each group.The control group was treated with metoprolol,and the observation group was treated with salkubatroxartan combined with metoprolol for 6 months.The clinical effects,the left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD) and brachial artery flow mediated vasodilation function(FDM),the levels of endothelin-1(ET-1),nitric oxide(NO),sST2,AngII and IGFBP7,and the adverse reactions of the two groups were compared.Results:After treatment,the total effective rate in the observation group was 91.49%,which was significantly higher than 77.42% in the control group(P< 0.05).LVEF and FMD in the observation group were significantly higher than those in the control group(P< 0.05),and LVEDD and LVESD were significantly lower than those in the control group(P< 0.05).After treatment,the levels of serum sT2,AngII and ET-1 in the observation group were significantly lower than those in the control group(P< 0.05),and the levels of IGFBP7 and NO were significantly higher than those in the control group(P< 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P> 0.05).Conclusion:Salkubatroxartan combined with metoprolol can improve the therapeutic effect of CHF in patients with coronary heart disease,enhance cardiac function and vascular endothelial function,and regulate the expression of serum sST2,AngII and IGFBP7.

关 键 词：冠心病 慢性心力衰竭 心功能 沙库巴曲缬沙坦 美托洛尔 可溶性ST2 胰岛素样生长因子结合蛋白7 

分 类 号：R541.4[医药卫生—心血管疾病] R541.6[医药卫生—内科学]